| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Galera Therapeutics, Inc.
13D/A
GRTX · 36338D108
|
30.2% |
5/29/2026
Event 5/15/2026
|
||||
| Emerald Bioventures, LLC | 30.2% | |||||
| Timothy Opler | 30.2% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.